Drug interaction study of GSK3772701 in healthy adults aged 18-55
Treatments studied
Part of Infections clinical trials.
This trial tests how a new drug (GSK3772701) interacts with another common drug (midazolam) in healthy volunteers. It aims to see if one affects how the other works in the body and will help determine safe dosing for future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 55 years old
- You must weigh at least 110 pounds (50 kg) and have a body-mass index between 18 and 30
- You must be in good general health, with no major heart, lung, liver, kidney, blood or other chronic diseases
- You must not be pregnant or breastfeeding, and if you could become pregnant, you must use highly effective birth control during and for a short time after the study
- You must not have used any prescription or over-the-counter medications or supplements in the past 7 days, or any investigational drugs in the past 3 months
- You must not smoke or use nicotine products, drink heavily, or use recreational drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.
This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.
This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
This study checks how a new medicine (NTQ5082) interacts with another drug (midazolam) in healthy people. It helps doctors understand if the new medicine changes how midazolam works, which is important for future patients.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.